Dechra is an international specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture and sales and marketing of high quality products exclusively for veterinarians worldwide. Our key focus therapeutic areas are: • Endocrinology • Dermatology • Anaesthesia and analgesia • Ophthalmology • Cardiovascular disease • Equine locomotion • Food producing animal antimicrobials • And pet diets
Type
Public
HQ
Lostock Gralam, GB
Founded
1997
Size (employees)
1,338 (est)+3%
Website
dechra.com
Dechra Pharmaceuticals was founded in 1997 and is headquartered in Lostock Gralam, GB
Report incorrect company information

Dechra Pharmaceuticals Office Locations

Dechra Pharmaceuticals has offices in Frogner, Warszawa, Montigny-le-Bretonneux, Aulendorf and in 12 other locations
Lostock Gralam, GB (HQ)
24 Cheshire Avenue Cheshire Business Park
Hadnall, GB
Sansaw Business Park
Skipton, GB
Snaygill Industrial Estate, Keighley Road
Dornbirn, AT
Hintere Achmühlerstraße 1A
Pointe-Claire, CA
1 Holiday Avenue, East Tower Suite 345
Uldum, DK
Mekuvej 9
Show all (16)
Report incorrect company information

Dechra Pharmaceuticals Financials and Metrics

Dechra Pharmaceuticals Revenue

Dechra Pharmaceuticals's revenue was reported to be £247.56 m in FY, 2016 which is a 21.7% increase from the previous period.
GBP

Revenue (FY, 2016)

247.6 m

Revenue growth (FY, 2015 - FY, 2016), %

21.7%

Gross profit (FY, 2016)

132.4 m

Gross profit margin (FY, 2016), %

53.5%

Net income (FY, 2016)

12.5 m

Cash (30-Jun-2016)

39.1 m
GBPFY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

137.2 m145.9 m145.5 m156.4 m170.2 m179.3 m186.8 m208.2 m232.5 m253.8 m189.2 m193.6 m203.5 m247.6 m

Revenue growth, %

2%5%22%

Cost of goods sold

123.8 m131.4 m128.6 m137.2 m149.7 m156.3 m161.4 m178.5 m199.2 m217 m88.5 m85.9 m87.3 m115.1 m

Gross profit

13.4 m14.5 m16.9 m19.2 m20.5 m23 m25.4 m29.7 m33.3 m36.9 m100.7 m107.7 m116.1 m132.4 m
GBPFY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2014FY, 2015FY, 2016

Cash

4.2 m4.7 m9.2 m4 m13.9 m19.7 m17.2 m26.8 m45.9 m39.1 m

Accounts Receivable

16.6 m18.7 m20.7 m23.2 m24.6 m26.8 m31.3 m31.8 m33.5 m34 m28.3 m27.7 m59.2 m

Inventories

9.3 m11.7 m16.2 m16.5 m19.3 m17.3 m17 m20.4 m22 m25.7 m

Current Assets

31.3 m36 m47.9 m44.6 m45.1 m45.3 m49.9 m68 m77 m79.1 m86.3 m108.6 m162.5 m
GBPFY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2014FY, 2015FY, 2016

Net Income

9 k171 k1.4 m3 m5.1 m3.8 m5.1 m6.3 m7.6 m8.8 m

Cash From Operating Activities

6.4 m5.4 m12 m3.5 m6.4 m6.5 m10.6 m13.2 m9.5 m9.2 m11.5 m41 m43.6 m

Dividends Paid

1.9 m2.1 m2.1 m2.4 m2.7 m2.8 m3.6 m

Cash From Financing Activities

39.9 m(1.4 m)(2.5 m)2.7 m(765 k)(3.4 m)(2.6 m)11.8 m(2.9 m)(6.7 m)(92.1 m)(14.8 m)125.3 m
GBPY, 2016

Revenue/Employee

286.9 k

Financial Leverage

2 x
Show all financial metrics
Report incorrect company information

Dechra Pharmaceuticals Online and Social Media Presence

Embed Graph
Report incorrect company information

Dechra Pharmaceuticals News and Updates

Pet Oral Care Market by Key Manufacturers (Allaccem, Inc., Ceva Sante Animale S.A., Colgate-Palmolive Company, Dechra Pharmaceuticals Plc. ) Forecast to 2025

ReportsWeb.com has announced the addition of the “Global Pet Oral Care Market Size Status and Forecast 2025” The report detailed insights about the aspects responsible for augmenting as well as restraining market growth. Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information

Dechra Pharmaceuticals Company Life and Culture

Report incorrect company information